10x Genomics, Inc.
67.29USD
+1.6900 (+2.58%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.02▲ | $-0.04 | 2 | 0 |
| Next quarter | $-0▲ | $-0.01 | 1 | 1 |
| Current year | $0.11▲ | $0 | 1 | 0 |
| Next year | $0.2▲ | $0.2 | 1 | 0 |
Beat in 4 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.02 | $0.03 | +0.04 (+258.4%) |
| 2026-03-31 | $-0.06 | $0.07 | +0.13 (+219.2%) |
| 2025-12-31 | $-0.04 | $0.07 | +0.11 (+276.3%) |
| 2025-09-30 | $-0.07 | $-0.02 | +0.05 (+67.4%) |
154 ratings from 21 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| UBS | Maintained | Neutral | $20 $68 | Sep 9, 2026 |
| RBC Capital | Initiated | Sector Perform | $70 | Sep 1, 2026 |
| Stephens & Co. | Maintained | Overweight | $50 $65 | Aug 12, 2026 |
| Piper Sandler | Maintained | Neutral | $42 $47 | Aug 10, 2026 |
| Canaccord Genuity | Maintained | Buy | $50 $60 | Aug 10, 2026 |
| Citigroup | Maintained | Neutral | $45 $50 | Aug 7, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $37 $40 | Aug 7, 2026 |
| Leerink Partners | Maintained | Market Perform | $23 $40 | Jul 17, 2026 |
| Canaccord Genuity | Maintained | Buy | $32 $50 | Jul 14, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $22 $37 | Jul 9, 2026 |
| Citigroup | Maintained | Neutral | $24 $45 | Jul 8, 2026 |
| Piper Sandler | Maintained | Neutral | $20 $42 | Jul 1, 2026 |
| Barclays | Maintained | Overweight | $30 $40 | Jun 24, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $20 $22 | May 12, 2026 |
| JP Morgan | Maintained | Neutral | $17 $20 | May 12, 2026 |
| Canaccord Genuity | Maintained | Buy | $22 $32 | Apr 20, 2026 |
| B of A Securities | Maintained | Neutral | $21 $30 | Apr 20, 2026 |
| Barclays | Maintained | Overweight | $22 $30 | Apr 14, 2026 |
| Citigroup | Maintained | Neutral | $18 $24 | Apr 7, 2026 |
| William Blair | Upgraded from Market Perform | Outperform | — | Mar 31, 2026 |
| Stifel | Maintained | Buy | $20 $25 | Mar 2, 2026 |
| UBS | Maintained | Neutral | $14 $20 | Feb 20, 2026 |
| Stifel | Maintained | Buy | $15 $20 | Feb 13, 2026 |
| TD Cowen | Maintained | Hold | $18 $19 | Feb 13, 2026 |
| Leerink Partners | Maintained | Market Perform | $22 $20 | Jan 27, 2026 |
67 filings from 10 insiders · 8 buy / 14 sell over 6m
Officers and directors of TXG, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| STUELPNAGEL JOHN RDirector | Sell | 6.2k | $62.61 | $387k | Sep 3, 2026 |
| STUELPNAGEL JOHN RDirector | Sell | 6.8k | $62.11 | $423k | Sep 3, 2026 |
| STUELPNAGEL JOHN RDirector | Sell | 7.0k | $60.66 | $425k | Sep 3, 2026 |
| Saxonov SergeDirector; Officer, Chief Executive Officer | Gift | 100 | — | — | Sep 1, 2026 |
| SAXONOV SERGE WILSONChief Executive Officer | Sell | 10.5k | $63.02 | $668k | Aug 26, 2026 |
| SAXONOV SERGE WILSONChief Executive Officer | Sell | 18.5k | $63.02 | $1.17M | Aug 24, 2026 |
| SULIMAN SHEHNAAZDirector | Sell | 2.2k | $62.73 | $140k | Aug 24, 2026 |
| TAICH ADAMChief Financial Officer | Sell | 17.2k | $63.02 | $1.08M | Aug 24, 2026 |
| HINDSON BENJAMIN JPresident | Sell | 13.8k | $63.02 | $871k | Aug 24, 2026 |
| SAXONOV SERGE WILSONChief Executive Officer | Gift | 4.0k | — | — | Aug 20, 2026 |
| TEICHMANN SARAH A.Director | Sell | 7.6k | $57.15 | $432k | Aug 14, 2026 |
| STUELPNAGEL JOHN RDirector | Sell | 20.0k | $57.58 | $1.16M | Aug 11, 2026 |
| SAXONOV SERGE WILSONChief Executive Officer | Sell | 30.0k | $33.29 | $1.03M | Jun 22, 2026 |
| SULIMAN SHEHNAAZDirector | Sell | 5.7k | $32.59 | $187k | Jun 16, 2026 |
| MATEO ALAN V.Director | Grant | 8.8k | — | — | Jun 4, 2026 |
| KOSARAJU SRIDHARDirector | Grant | 8.8k | — | — | Jun 4, 2026 |
| SULIMAN SHEHNAAZDirector | Grant | 8.8k | — | — | Jun 4, 2026 |
| TEICHMANN SARAH A.Director | Grant | 8.8k | — | — | Jun 4, 2026 |
| POPOVITS KIMBERLY JDirector | Grant | 8.8k | — | — | Jun 4, 2026 |
| STUELPNAGEL JOHN RDirector | Grant | 8.8k | — | — | Jun 4, 2026 |
No analyst notes on TXG yet.
Analyst Ratings
14 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 1 | 5 | 11 | 0 | 0 | Hold2.59 |
| 1 mo ago | 1 | 5 | 10 | 0 | 0 | Hold2.56 |
| 2 mo ago | 1 | 5 | 10 | 0 | 0 | Hold2.56 |
| 3 mo ago | 1 | 5 | 10 | 0 | 0 | Hold2.56 |